
A phase II randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of intra-articular injections of SB-061 in knee osteoarthritis patients over 52 weeks. Despite being well-tolerated, SB-061 did not demonstrate significant improvement in the primary endpoint (WOMAC pain score) at Week 8 or any other secondary endpoints, such as WOMAC function, ICOAP, PGA, or 20-meter walk test, compared to placebo. The study concluded that SB-061 is safe but ineffective in reducing knee pain or improving other OA symptoms.
Like
Save
Share